Episode
A conversation with Matt Ketchum
We interview a patient who has lived through both chronic pain and substance use dependency before and during the opioid ...
Retaliatory healthcare laws
Most healthcare laws interpret healthcare behavior subjectively and do not rely on any medical basis. This makes most healthcare laws ...
A conversation with Dr. Clement
It has been said that passion fuels purpose. And there is no one more passionate about rectifying the wrongs done ...
A conversation with Dr. Nabarun Dasgupta
We release a special podcast in which we interview the amazing Dr. Nabarun Dasgupta, Senior Scientist, Injury Prevention Research Center ...
A conversation with Dr. Forrest Tenant
Today we interview Dr. Forrest Tenant, a physician pioneer in the field of pain management and substance use dependency who ...
Much ado about boosters
We go beyond the data and narratives on COVID-19 boosters to discuss vaccine equity.
A conversation with Dr. William Cooke
We are proud to release a special podcast in which we interview the incomparable Dr. William Cooke, author of Canary ...
America’s abortion obsession
We explore the origins and current status of abortion laws in the United States, and expose a flaw in applying ...
Representing healthcare
Healthcare filled with biases that form relative to our frame of reference. Not from any specific component, but through the ...
Why Scientists Lie
We discuss the concept of lying in terms of heuristics and behavioral economics, exploring how different people simplify complex concepts differently, ...
Vaccine willingness and mandates
We explore the debate surrounding vaccines, vaccine mandates, and the willingness to obtain a vaccine - analyzing the argument in ...
Overcoming outcomes bias in healthcare
Healthcare is defined by data. But data is nothing more than an outcome, susceptible to outcomes bias. We explore this ...
Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more